News stories about Summit Therapeutics (NASDAQ:SMMT) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Summit Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.4482181186718 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s scoring:
- Summit Therapeutics plc (SMMT) Rose to $13.00 on Apr, 9 (thecasualsmart.com)
- Summit Therapeutics plc (SMMT) Skyrocketed to $13.00 (styleonfleek365.com)
- Summit Therapeutics (SMMT) Scheduled to Post Earnings on Wednesday (americanbankingnews.com)
- Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 (markets.financialcontent.com)
- Antibiotics Help C. diff Compete for Nutrients Needed to Survive & Thrive (contagionlive.com)
SMMT opened at $13.38 on Wednesday. The stock has a market cap of $170.14, a P/E ratio of -6.08 and a beta of 0.79. Summit Therapeutics has a fifty-two week low of $8.80 and a fifty-two week high of $16.86.
Several analysts have recently issued reports on SMMT shares. ValuEngine upgraded shares of Summit Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Oppenheimer upped their target price on shares of Summit Therapeutics from $24.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, January 26th. Zacks Investment Research lowered shares of Summit Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 28th. BTIG Research initiated coverage on shares of Summit Therapeutics in a research note on Tuesday, February 13th. They issued a “buy” rating and a $33.00 target price for the company. Finally, SunTrust Banks initiated coverage on shares of Summit Therapeutics in a research report on Thursday, January 4th. They set a “buy” rating and a $24.00 price target for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $24.17.
Summit Therapeutics Company Profile
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.